AestheFill vs Juvelook
AestheFill and Juvelook share the PDLLA acronym, but they are different finished-product systems. The commonly documented AestheFill vial contains 154 mg of poly-D,L-lactic acid (PDLLA) microspheres and 46 mg of carboxymethylcellulose (CMC). The Korean Juvelook family combines PDLLA with hyaluronic acid (HA) and currently includes 30 mg, 50 mg, and 200 mg presentations.
Composition, preparation, intended use, evidence, and safety assumptions cannot be transferred between the brands. This is not a claim that either product is preferable.
Compact comparison
Section titled “Compact comparison”| Field | AestheFill | Juvelook family |
|---|---|---|
| Material system | 154 mg PDLLA microspheres + 46 mg CMC in the commonly documented 200 mg vial (AestheFill consensus 🔗) | PDLLA + HA; exact quantities depend on the named presentation (VAIM Korean product information 🔗) |
| Current publicly described presentation | Lyophilized granules or pellets requiring reconstitution in sterile water; the cited consensus describes the 200 mg vial (AestheFill consensus 🔗) | Juvelook i and Skin: 25.5 mg PDLLA + 4.5 mg HA; Juvelook: 42.5 mg + 7.5 mg; Volume and G: 170 mg + 30 mg (VAIM Korean product information 🔗) |
| Suspending or hybrid component | CMC forms the suspending phase after preparation; the particles do not dissolve during reconstitution (reconstitution commentary 🔗) | HA is an explicit component of the supplied hybrid product; the Korean page does not describe it as a conventional cross-linked HA gel (VAIM Korean product information 🔗) |
| Preparation boundary | Requires product-specific reconstitution; published consensus and experimental methods are not a universal local IFU (AestheFill consensus 🔗) | Requires presentation-specific preparation; published study protocols do not establish one family-wide method (50 mg Juvelook study 🔗) |
| Korean intended-use evidence | A current public MFDS record or Korean IFU is not established by the manufacturer page reviewed here; REGEN states that intended use varies by country (REGEN AestheFill 🔗) | VAIM’s Korean page gives one shared public wording: subcutaneous injection of polylactide and HA for temporary improvement of adult facial wrinkles through physical restoration (VAIM Korean product information 🔗) |
| Company relationship supported here | REGEN presents AestheFill as its product and records obtaining a Korean manufacturing license for AestheFill and PowerFill in April 2014 (REGEN product page 🔗; REGEN history 🔗) | VAIM operates the Korean product source; an Italian Ministry safety record identifies VAIM Co., Ltd. as manufacturer of the named device (VAIM product page 🔗; Italian Ministry of Health 🔗) |
The company evidence is deliberately narrow. A historical Korean manufacturing-license statement does not establish the current legal manufacturer or approval holder in every market. Likewise, the Italian record confirms a manufacturer role for the device in that safety notice, not every registration, distributor, or presentation worldwide.
The key distinction is the finished formulation
Section titled “The key distinction is the finished formulation”Calling both products “PDLLA” hides the variables most likely to affect practical interpretation:
- exact vial and total material amount
- CMC suspension versus HA-containing hybrid formulation
- particle architecture
- preparation volume and process
- intended tissue level and indication
- whether a paper studied the exact current presentation
In prepared AestheFill, CMC helps suspend PDLLA microspheres. In Juvelook, HA is a listed component of the supplied product. Prepared fluid and edema may affect the early appearance of either product, while HA remains visible in Juvelook interpretation. Later tissue response must be tied to the exact product, study, anatomy, and follow-up period.
The HA in Juvelook does not make the entire particulate implant equivalent to an HA-only gel. It also does not establish that all product effects or complications can be completely reversed with hyaluronidase.
“Juvelook” is not one vial
Section titled ““Juvelook” is not one vial”| Korean presentation | Listed composition | Interpretation boundary |
|---|---|---|
| Juvelook i; Juvelook Skin | 25.5 mg PDLLA + 4.5 mg HA, 30 mg total (VAIM product page 🔗) | Same listed quantities do not prove identical particle specifications, package, preparation, or instructions |
| Juvelook | 42.5 mg PDLLA + 7.5 mg HA, 50 mg total (VAIM product page 🔗) | Evidence using this presentation should not be assigned automatically to Volume |
| Juvelook Volume; Juvelook G | 170 mg PDLLA + 30 mg HA, 200 mg total (VAIM product page 🔗) | Volume is a named presentation, not a generic label for every 200 mg product |
The preliminary whole-face study often cited for Juvelook used the 50 mg composition and a study-specific mixture. It did not test AestheFill or establish instructions for Juvelook Volume (Journal of Cosmetic Dermatology 🔗).
Korean intended use and regional limits
Section titled “Korean intended use and regional limits”VAIM’s Korean page presents all five Juvelook names as Class IV soft-tissue repair material (조직수복용재료) and displays the same intended-use wording: subcutaneous injection of polylactide and HA for temporary improvement of adult facial wrinkles through physical restoration (VAIM Korean product information 🔗).
That company-hosted Korean information does not establish that the five products share an identical IFU or preparation method. Nor does it convert company media positioning for thin areas, pores, scars, deeper wrinkles, or body use into the approved purpose. Overseas names, registrations, distributors, and published off-label techniques require their own regional evidence.
REGEN’s AestheFill page instead gives a general description—improvement of facial wrinkles and folds—and explicitly directs readers to information approved in their country (REGEN AestheFill 🔗). Without the controlling Korean product record or IFU, that wording should not be rewritten as the same Korean intended-use statement shown for Juvelook.
Preparation must remain product-specific
Section titled “Preparation must remain product-specific”The AestheFill consensus recommends 7–8 mL sterile water for the 200 mg vial in a Brazilian expert-consensus context, but that recommendation is not a universal regulatory label (AestheFill consensus 🔗). Juvelook studies also use differing preparation and injection protocols. Those methods describe study interventions; they do not establish one family-wide instruction.
Always record the exact Juvelook presentation rather than citing “Juvelook” alone. A named 30 mg presentation and a named 200 mg presentation should not be treated as the same product merely because the brand family is shared.
Evidence boundaries
Section titled “Evidence boundaries”A randomized split-face study comparing Juvelook Volume with a PLLA product reported improvement on both sides through 24 weeks. One Juvelook Volume-treated participant developed moderate swelling and tenderness attributed by the authors to localized excess HA; this is a product-and-protocol observation with relatively short follow-up, not a class-wide PDLLA rate (split-face study 🔗).
The broader PDLLA evidence base remains heterogeneous in product, anatomy, preparation, and outcome measures (PDLLA review 🔗).
Practitioner takeaway
Section titled “Practitioner takeaway”The useful question is not “which PDLLA brand?” but “which exact formulation and presentation matches the documented treatment objective?” Continue to the individual AestheFill and Juvelook pages, the REGEN Biotech and VAIM role pages, or the focused Juvelook vs Juvelook Volume comparison.